Dexamethasone in Hospitalized Patients with Covid-19
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
SciScore for 10.1101/2020.06.22.20137273: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from all patients or from a legal representative if they were too unwell or unable to provide consent.
IRB: The trial was conducted in accordance with the principles of the International Conference on Harmonization–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).Randomization Trial design and participants: The RECOVERY trial is an investigator-initiated, individually randomized, controlled, open-label, adaptive platform trial to evaluate the effects of potential treatments in … SciScore for 10.1101/2020.06.22.20137273: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Consent: Written informed consent was obtained from all patients or from a legal representative if they were too unwell or unable to provide consent.
IRB: The trial was conducted in accordance with the principles of the International Conference on Harmonization–Good Clinical Practice guidelines and approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and the Cambridge East Research Ethics Committee (ref: 20/EE/0101).Randomization Trial design and participants: The RECOVERY trial is an investigator-initiated, individually randomized, controlled, open-label, adaptive platform trial to evaluate the effects of potential treatments in patients hospitalized with COVID-19. Blinding Participants and local study staff were not blinded to the allocated treatment. Power Analysis As the trial progressed, the trial Steering Committee, blinded to the results of the study treatment comparisons, formed the view that, if 28-day mortality was 20% then a comparison of at least 2000 patients allocated to active drug and 4000 to usual care alone would yield at least 90% power at two-sided P=0.01 to detect a clinically relevant absolute difference of 4 percentage points between the two groups (a proportional reduction of one-fifth). Sex as a biological variable Pregnant or breast-feeding women were eligible. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
Identifier Status Title NCT04381936 Recruiting Randomised Evaluation of COVID-19 Therapy Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
-
-
SciScore for 10.1101/2020.06.22.20137273: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Written informed consent was obtained from all patients or from a legal representative if they were too unwell or unable to provide consent. Randomization Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. Blinding Participants and local study staff were not blinded to the allocated treatment. Power Analysis As the trial progressed, the trial Steering Committee, blinded to the results of the study treatment comparisons, formed the view that, if 28-day mortality was 20% then … SciScore for 10.1101/2020.06.22.20137273: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement Written informed consent was obtained from all patients or from a legal representative if they were too unwell or unable to provide consent. Randomization Methods: The Randomised Evaluation of COVID-19 therapy (RECOVERY) trial is a randomized, controlled, open-label, adaptive, platform trial comparing a range of possible treatments with usual care in patients hospitalized with COVID-19. Blinding Participants and local study staff were not blinded to the allocated treatment. Power Analysis As the trial progressed, the trial Steering Committee, blinded to the results of the study treatment comparisons, formed the view that, if 28-day mortality was 20% then a comparison of at least 2000 patients allocated to active drug and 4000 to usual care alone would yield at least 90% power at two-sided P=0.01 to detect a clinically relevant absolute difference of 4 percentage points between the two groups (a proportional reduction of one-fifth). Sex as a biological variable Pregnant or breast-feeding women were eligible. Table 2: Resources
Software and Algorithms Sentences Resources Funding The RECOVERY trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) (Grant reference: MC_PC_19056) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. Oxford Biomedical Research Centresuggested: NoneResults from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.
Results from OddPub: We did not find a statement about open data. We also did not find a statement about open code. Researchers are encouraged to share open data when possible (see Nature blog).
About SciScore
SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore is not a substitute for expert review. SciScore checks for the presence and correctness of RRIDs (research resource identifiers) in the manuscript, and detects sentences that appear to be missing RRIDs. SciScore also checks to make sure that rigor criteria are addressed by authors. It does this by detecting sentences that discuss criteria such as blinding or power analysis. SciScore does not guarantee that the rigor criteria that it detects are appropriate for the particular study. Instead it assists authors, editors, and reviewers by drawing attention to sections of the manuscript that contain or should contain various rigor criteria and key resources. For details on the results shown here, including references cited, please follow this link.
-
